Breast Surgery Practice Questions

Q: A 27-year-old woman requests a mammogram due to a strong family history of early-onset breast cancer. Which of the following factors would significantly increase this patient's risk for breast cancer?

BRCA1 mutation. **Explanation:** **1. Why BRCA1 mutation is correct:** The **BRCA1 mutation** is a high-penetrance germline mutation that significantly increases the lifetime risk of breast cancer (up to 60-80%) and ovarian cancer (up to 40%). In a young patient (27 years old) with a strong family history, genetic predisposition is the most significant risk factor. BRCA1-associated breast cancers are often "triple-negative" and occur at an earlier age compared to the general population. **2. Why the other options are incorrect:** * **Multiparity (A):** This is actually a **protective factor**. Early first full-term pregnancy and having multiple children reduce the total number of ovulatory cycles and promote terminal differentiation of breast epithelium, lowering risk. * **High-fiber diet (B):** This is generally considered a **protective or neutral factor**. Diets high in fiber and low in fat are associated with lower circulating estrogen levels, potentially reducing risk. * **Oral contraceptive use (C):** While some studies suggest a very slight, transient increase in risk during active use, it is **not as significant** as a genetic mutation. Furthermore, OCPs are known to significantly *decrease* the risk of ovarian and endometrial cancers. **Clinical Pearls for NEET-PG:** * **Screening in High Risk:** For BRCA carriers, screening starts early (age 25) with **Annual MRI**, as mammography is less sensitive in the dense breast tissue of young women. * **BRCA1 vs. BRCA2:** BRCA1 is on Chromosome **17q** (associated with Triple Negative Breast Cancer); BRCA2 is on Chromosome **13q** (associated with Male Breast Cancer). * **Gail Model:** The most commonly used tool to estimate the 5-year and lifetime risk of invasive breast cancer. * **Li-Fraumeni Syndrome:** Another high-yield genetic cause involving the **p53 mutation**, leading to early-onset breast cancer and sarcomas.

Q: What procedure is depicted?

Sentinel Lymphnode Biopsy. ***Sentinel Lymphnode Biopsy*** - The procedure involves identification of the **first draining lymph node** from the tumor using **blue dye** and **gamma probe** detection methods. - Characteristic features include **axillary node identification** and **minimal invasive technique** to assess lymphatic spread in breast cancer. *Brachytherapy* - Involves placement of **radioactive sources** directly into or near the tumor tissue for localized radiation therapy. - Requires **specialized radioactive implants** and **shielding protocols**, not the blue dye and probe techniques shown. *USG* - **Ultrasonography** is a **non-invasive imaging technique** using sound waves to visualize internal structures. - Does not involve **surgical incision**, **dye injection**, or **radioactive probe** usage as seen in the procedure. *Lateral Pectoral Block* - An **anesthetic technique** targeting the **lateral pectoral nerve** for pain management during breast procedures. - Involves **nerve block injection** with local anesthetics, not **lymph node identification** or **dye-guided techniques**.

Q: Inflammatory carcinoma is classified under which TNM staging category?

T4d. ### Explanation **Correct Answer: D. T4d** **Medical Concept:** Inflammatory Breast Cancer (IBC) is a distinct, highly aggressive clinical entity characterized by rapid onset of erythema, edema (peau d'orange), and warmth involving at least one-third of the breast. In the TNM staging system (AJCC 8th Edition), IBC is specifically categorized as **T4d**. This classification is based on **clinical findings** rather than purely pathological ones, as the hallmark "dermal lymphatic invasion" by tumor emboli is not required for the diagnosis if the clinical criteria are met. **Analysis of Incorrect Options:** * **T4a:** Refers to tumor extension to the **chest wall** (involvement of ribs, intercostal muscles, or serratus anterior; pectoralis muscle involvement alone does not qualify). * **T4b:** Refers to **skin changes** such as edema (including peau d'orange), ulceration, or satellite skin nodules, but these do *not* meet the criteria for inflammatory carcinoma (i.e., they involve less than one-third of the breast). * **T4c:** Represents a combination of both **T4a and T4b** (extension to chest wall plus skin ulceration/edema). **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Diagnosis:** IBC is primarily a clinical diagnosis. The classic **"Peau d'orange"** appearance is due to the obstruction of dermal lymphatics by tumor emboli. * **Staging:** All T4d tumors are automatically classified as at least **Stage IIIB**, regardless of nodal status (if N0). * **Management:** The standard of care is **Multimodality Therapy**: Neoadjuvant Chemotherapy (NACT) followed by Modified Radical Mastectomy (MRM) and Radiotherapy. *Never* start with primary surgery. * **Differential Diagnosis:** Must be differentiated from acute mastitis; if a suspected "breast infection" does not respond to antibiotics within 1–2 weeks, a biopsy is mandatory to rule out IBC.

Q: Adjuvant therapy after mastectomy is needed in all of the following situations except:

Low risk, no node. **Explanation:** The decision to initiate adjuvant therapy (chemotherapy, hormonal therapy, or radiotherapy) after a mastectomy is based on the risk of systemic recurrence and the biological profile of the tumor. **Why "Low risk, no node" is the correct answer:** Adjuvant therapy is generally withheld in patients with **low-risk, node-negative (N0)** disease. This typically includes patients with small tumors (usually <0.5 cm or T1a), favorable histological subtypes (e.g., tubular or mucinous carcinoma), and strongly hormone-receptor-positive status with a low proliferative index (Ki-67). In these cases, the risk of recurrence is so low that the potential toxicities of chemotherapy outweigh the marginal clinical benefit. **Analysis of Incorrect Options:** * **High risk, node positive:** Presence of even a single positive lymph node (N1 or higher) significantly increases the risk of systemic spread, making adjuvant systemic therapy (usually chemotherapy) mandatory. * **ER/PR negative:** Tumors that lack hormone receptors do not respond to endocrine therapy (like Tamoxifen). Because these "Triple Negative" or "Basal-like" cancers are more aggressive, adjuvant chemotherapy is indicated even for relatively small tumors. * **Her-2-neu positive:** Overexpression of the HER2 protein signifies an aggressive phenotype. These patients require adjuvant chemotherapy combined with targeted therapy (e.g., Trastuzumab) to improve survival outcomes. **Clinical Pearls for NEET-PG:** * **Sentinel Lymph Node Biopsy (SLNB):** The gold standard for axillary staging in clinically N0 patients to determine the need for adjuvant therapy. * **Oncotype DX:** A genomic assay used specifically in ER+, HER2-, node-negative patients to decide if chemotherapy can be safely omitted. * **Radiotherapy after Mastectomy (PMRT):** Indicated if the tumor is >5 cm (T3), involves the chest wall/skin (T4), or if there are ≥4 positive nodes.

Q: Which of the following is not a risk factor for breast carcinoma?

Early menopause. **Explanation:** The risk of breast carcinoma is primarily linked to the **cumulative lifetime exposure of breast tissue to estrogen**. Estrogen promotes the proliferation of mammary epithelial cells, increasing the likelihood of DNA mutations. **Why Early Menopause is the Correct Answer:** Early menopause (cessation of menstruation before age 45) is actually a **protective factor**, not a risk factor. It shortens the duration of the "estrogen window," thereby reducing the total lifetime exposure to ovarian hormones. Conversely, **late menopause** (after age 55) is a well-known risk factor. **Analysis of Incorrect Options:** * **Saturated Fatty Acids:** High dietary intake of saturated fats and obesity (especially post-menopausal) are linked to increased risk. In obese women, peripheral conversion of androstenedione to estrone in adipose tissue increases circulating estrogen levels. * **Nulliparous Women:** Women who have never carried a pregnancy to term have higher risk because they do not experience the hormonal "break" provided by pregnancy and lactation. Early first pregnancy (before age 20) is protective. * **Estrogen Unopposed by Progesterone:** Prolonged exposure to estrogen without the balancing effect of progesterone (e.g., Hormone Replacement Therapy or early menarche) stimulates ductal hyperplasia, increasing malignancy risk. **High-Yield Clinical Pearls for NEET-PG:** * **The "Estrogen Window" Concept:** Risk increases with early menarche ( 55 years). * **BRCA Mutations:** BRCA1 (Chromosome 17) and BRCA2 (Chromosome 13) are the most significant genetic risk factors. * **Breastfeeding:** For every 12 months of breastfeeding, the relative risk of breast cancer decreases by approximately 4.3%. * **Atypical Hyperplasia:** Finding atypical ductal or lobular hyperplasia on biopsy increases risk by 4–5 times.

Q: Which of the following is NOT a risk factor for increased incidence of relapse in stage I carcinoma of the breast?

Decreased Her-2/neu oncogene expression. **Explanation:** In breast cancer management, prognostic factors are used to predict the risk of recurrence and guide adjuvant therapy. The question asks for the factor that is **NOT** associated with an increased risk of relapse. **1. Why Option D is Correct:** The **Her-2/neu (c-erbB2)** oncogene is a transmembrane tyrosine kinase receptor. **Increased expression (amplification)** of this gene is associated with aggressive tumor behavior, higher grade, and a significantly increased risk of relapse. Therefore, **decreased expression** would theoretically imply a better prognosis or a baseline risk, rather than an increased risk of relapse. **2. Analysis of Incorrect Options (Risk Factors for Relapse):** * **A. Negative ER/PR status:** Estrogen and Progesterone receptor-negative tumors are generally more aggressive, have a higher histological grade, and do not respond to endocrine therapies (like Tamoxifen), leading to a higher incidence of relapse. * **B. High S-phase fraction:** This is a measure of cellular proliferation (the percentage of cells replicating DNA). A high S-phase fraction indicates a rapidly dividing, aggressive tumor with a higher likelihood of recurrence. * **C. Aneuploidy:** DNA aneuploidy (abnormal amount of DNA) is a marker of genetic instability. Aneuploid tumors have a worse prognosis compared to diploid tumors in Stage I breast cancer. **Clinical Pearls for NEET-PG:** * **Most important prognostic factor** for breast cancer: Number of axillary lymph nodes involved. * **Most important prognostic factor in Node-Negative (Stage I) disease:** Tumor size. * **Triple Negative Breast Cancer (TNBC):** Lacks ER, PR, and Her-2 expression; carries the worst prognosis among molecular subtypes. * **Luminal A:** (ER/PR +, Her-2 -, low Ki-67) has the best prognosis.

Question 1

A 27-year-old woman requests a mammogram due to a strong family history of early-onset breast cancer. Which of the following factors would significantly increase this patient's risk for breast cancer?

Accepted Answer

BRCA1 mutation

Answer

Multiparity

Answer

High-fiber diet

Answer

Oral contraceptive use

Question 2

A 62-year-old woman with a family history of breast cancer (her mother died of breast cancer at age 63) is concerned about her future risk. Which of the following features is a recognized risk factor for breast cancer?

Accepted Answer

Early onset of menarche

Answer

Late onset of menopause

Answer

Late-life radiation exposure

Answer

Nulliparity

Question 3

In a patient with carcinoma breast stage T4b, as per TNM classification, what defines this stage?

Accepted Answer

Nipple retraction

Answer

Skin ulcer over the swelling

Answer

Dermal edema

Answer

Satellite nodules

Question 4

In a post-mastectomy patient, the suction drain is accidentally removed on the 2nd post-operative day, and the patient presents with oozing and swelling in the chest. What is the next best step in management?

Accepted Answer

Aspiration under aseptic conditions and apply pressure dressing

Answer

Open incision and pack with saline gauze

Answer

Reinsert the drain

Answer

Wait and watch

Question 5

What procedure is depicted?

Accepted Answer

Sentinel Lymphnode Biopsy

Answer

Brachytherapy

Answer

USG

Answer

Lateral Pectoral Block

Question 6

Inflammatory carcinoma is classified under which TNM staging category?

Accepted Answer

T4d

Answer

T4a

Answer

T4b

Answer

T4c

Question 7

Adjuvant therapy after mastectomy is needed in all of the following situations except:

Accepted Answer

Low risk, no node

Answer

High risk, node positive

Answer

Estrogen receptor/Progesterone receptor negative

Answer

Her-2-neu positive

Question 8

A 30-year-old female underwent lumpectomy for a 1.2x1 cm breast lesion with positive axillary nodes. She received adjuvant radiotherapy, tamoxifen, and chemotherapy. What is the recommended line of management for her follow-up?

Accepted Answer

Examination once every 3 months for one year, followed by yearly mammograms

Answer

Yearly bone scans

Answer

Liver function tests every 6 months

Answer

Follow-up by tumor markers every 6 months

Question 9

Which of the following is not a risk factor for breast carcinoma?

Accepted Answer

Early menopause

Answer

Saturated fatty acids

Answer

Nulliparous women

Answer

Estrogen unopposed by progesterone

Question 10

Which of the following is NOT a risk factor for increased incidence of relapse in stage I carcinoma of the breast?

Accepted Answer

Decreased Her-2/neu oncogene expression

Answer

Negative estrogen/progesterone receptor status

Answer

High S phase fraction

Answer

Aneuploidy

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?